Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.J&J has acquired heart failure implant maker V-Wave for up to $1.7 billion, while Medtronic reiterates its unchanged diabetes strategy despite a partnership with Abbott. Histosonics secured $102 million for a noninvasive tumor treatment using sound waves, and Edwards acquired Genesis' TAVR technology. The FDA approved NowDiagnostics' at-home syphilis test, offering results in 15 minutes with a drop of blood. The biotech industry remains strong in 2024, with startups thriving and technology advancements. Small biopharma and CROs are adopting multiple trial technologies, as per a recent survey.23andMe, known for consumer genetic testing, focuses on therapeutics development despite financial struggles and data breach lawsuits. Their lead candidate targets a new cancer treatment pathway using checkpoint inhibitors. Lilly's diabetes drug tirzepatide shows promise in reducing type 2 diabetes risk, while J&J's Rybrevant and Lazcluze combo is FDA-approved for lung cancer. Avidity and Kymera raised funds, Walgreens partnered with BARDA, and Merck licensed an antibody drug conjugate. Humana settles Medicare Part D fraud allegations, Steward hospitals in Massachusetts must sell five facilities, and McLaren Health Care faces another ransomware attack.Eli Lilly's tirzepatide demonstrates a 94% risk reduction for type 2 diabetes in overweight adults, and J&J's Rybrevant combo is the first chemo-free treatment for non-small cell lung cancer. Walgreens and BARDA collaborate to boost decentralized clinical trials, while three drugs are projected to drive drug price negotiation savings in 2026. Quality Assurance and Regulatory Affairs roles are crucial for market access, AbbVie and Genmab expand Tepkinly's European label, and biopharma companies like Lykos, Galera, and Grail announce staff reductions. AstraZeneca receives FDA approval for Imfinzi's perioperative use.Lykos restructures with significant staff cuts post-FDA rejection of their therapy, Acelyrin shifts focus to thyroid eye disease treatment after layoffs. Biotech IPO sizes are increasing despite slow IPO rates, Lilly opens an R&D hub in Boston, Ovid and Lexicon downsize staff. Stay informed with Biopharma Dive's comprehensive coverage of biotech and pharma industry news.